Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tamoxifen · Nolvadex, Soltamox

Small molecule · Antagonist of Estrogen receptor alpha (ESR1) · developed by Astrazeneca

Approved FDA, Dec 1977
2 Registered trials

What is Tamoxifen?

Tamoxifen is a nonsteroidal selective estrogen receptor modulator that competes with estrogen for binding to the estrogen receptor, reducing estrogen receptor signaling-dependent growth in breast tissue. It is studied in breast cancer and HER2-positive breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Nolvadex, Soltamox, ICI-47699, NSC-727681
Drug type
Small molecule
Targets
Estrogen receptor alpha (ESR1)
Mechanism
Antagonist of Estrogen receptor alpha (ESR1)
Pathways
estrogen receptor signaling, estrogen-response element DNA binding, TGF-beta production, IGF-1 signaling
Therapy area
Oncology
Developer
Astrazeneca
In trials of
LLY, ZYME
FDA status
Approved as Nolvadex, Soltamox (December 30, 1977), NDA017970 · FDA label
UNII
094ZI81Y45

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 29, 2021). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07287098 Phase 2 Breast Neoplasms Recruiting LLY
NCT05035836 Phase 2 Breast Cancer Recruiting ZYME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerBreast NeoplasmsHER2-positive

Other drugs acting on ESR1

Camizestrant FDA approved Ethinyl Estradiol/Levonorgestrel FDA approved Imlunestrant FDA approved Segesterone Acetate and Ethinyl Estradiol FDA approved Vepdegestrant FDA approved Giredestrant Phase 1/2 Zuclomiphene Phase 2

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.